BR Biopharma (BRBI) Competitors

BR Biopharma logo
$7.40 -0.22 (-2.89%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$7.42 +0.02 (+0.27%)
As of 11/20/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BRBI vs. LKSP, RILY, WTF, SIEB, and CAPN

Should you buy BR Biopharma stock or one of its competitors? BR Biopharma's main competitors and comparable companies include Lake Superior Acquisition (LKSP), B. Riley Financial (RILY), Waton Financial (WTF), Siebert Financial (SIEB), and Cayson Acquisition (CAPN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "investment banking & brokerage" industry.

How does BR Biopharma compare to Lake Superior Acquisition?

BR Biopharma (NASDAQ:BRBI) and Lake Superior Acquisition (NASDAQ:LKSP) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

In the previous week, BR Biopharma and BR Biopharma both had 1 articles in the media. Lake Superior Acquisition's average media sentiment score of 1.69 beat BR Biopharma's score of 0.00 indicating that Lake Superior Acquisition is being referred to more favorably in the news media.

Company Overall Sentiment
BR Biopharma Neutral
Lake Superior Acquisition Very Positive

Company Net Margins Return on Equity Return on Assets
BR BiopharmaN/A N/A N/A
Lake Superior Acquisition N/A N/A N/A

BR Biopharma has higher revenue and earnings than Lake Superior Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BR Biopharma$2.23B0.04$31.36M$0.1452.86
Lake Superior AcquisitionN/AN/AN/AN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BR Biopharma
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Lake Superior Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

BR Biopharma beats Lake Superior Acquisition on 2 of the 3 factors compared between the two stocks.

How does BR Biopharma compare to B. Riley Financial?

BR Biopharma (NASDAQ:BRBI) and B. Riley Financial (NASDAQ:RILY) are both small-cap finance companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

BR Biopharma has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, B. Riley Financial has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

50.2% of B. Riley Financial shares are owned by institutional investors. 29.4% of BR Biopharma shares are owned by company insiders. Comparatively, 27.8% of B. Riley Financial shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BR Biopharma and BR Biopharma both had 1 articles in the media. BR Biopharma's average media sentiment score of 0.00 equaled B. Riley Financial'saverage media sentiment score.

Company Overall Sentiment
BR Biopharma Neutral
B. Riley Financial Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BR Biopharma
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
B. Riley Financial
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

B. Riley Financial has a net margin of 8.83% compared to BR Biopharma's net margin of 0.00%. B. Riley Financial's return on equity of 190.02% beat BR Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
BR BiopharmaN/A N/A N/A
B. Riley Financial 8.83%190.02%4.62%

B. Riley Financial has lower revenue, but higher earnings than BR Biopharma. B. Riley Financial is trading at a lower price-to-earnings ratio than BR Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BR Biopharma$2.23B0.04$31.36M$0.1452.86
B. Riley Financial$967.60M0.12$307.42M$3.750.75

Summary

B. Riley Financial beats BR Biopharma on 8 of the 12 factors compared between the two stocks.

How does BR Biopharma compare to Waton Financial?

Waton Financial (NASDAQ:WTF) and BR Biopharma (NASDAQ:BRBI) are both small-cap finance companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Company Net Margins Return on Equity Return on Assets
Waton FinancialN/A N/A N/A
BR Biopharma N/A N/A N/A

Waton Financial has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, BR Biopharma has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Waton Financial
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BR Biopharma
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

BR Biopharma has higher revenue and earnings than Waton Financial.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Waton Financial$11.08M8.05-$15.15MN/AN/A
BR Biopharma$2.23B0.04$31.36M$0.1452.86

In the previous week, Waton Financial had 1 more articles in the media than BR Biopharma. MarketBeat recorded 2 mentions for Waton Financial and 1 mentions for BR Biopharma. Waton Financial's average media sentiment score of 0.42 beat BR Biopharma's score of 0.00 indicating that Waton Financial is being referred to more favorably in the media.

Company Overall Sentiment
Waton Financial Neutral
BR Biopharma Neutral

Summary

Waton Financial beats BR Biopharma on 4 of the 7 factors compared between the two stocks.

How does BR Biopharma compare to Siebert Financial?

BR Biopharma (NASDAQ:BRBI) and Siebert Financial (NASDAQ:SIEB) are both small-cap finance companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

BR Biopharma has higher revenue and earnings than Siebert Financial. Siebert Financial is trading at a lower price-to-earnings ratio than BR Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BR Biopharma$2.23B0.04$31.36M$0.1452.86
Siebert Financial$94.20M0.74$5.12M-$0.09N/A

1.5% of Siebert Financial shares are owned by institutional investors. 29.4% of BR Biopharma shares are owned by company insiders. Comparatively, 43.0% of Siebert Financial shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Siebert Financial had 4 more articles in the media than BR Biopharma. MarketBeat recorded 5 mentions for Siebert Financial and 1 mentions for BR Biopharma. Siebert Financial's average media sentiment score of 0.12 beat BR Biopharma's score of 0.00 indicating that Siebert Financial is being referred to more favorably in the news media.

Company Overall Sentiment
BR Biopharma Neutral
Siebert Financial Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BR Biopharma
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Siebert Financial
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

BR Biopharma has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market. Comparatively, Siebert Financial has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

BR Biopharma has a net margin of 0.00% compared to Siebert Financial's net margin of -3.36%. BR Biopharma's return on equity of 0.00% beat Siebert Financial's return on equity.

Company Net Margins Return on Equity Return on Assets
BR BiopharmaN/A N/A N/A
Siebert Financial -3.36%-3.88%-0.44%

Summary

BR Biopharma beats Siebert Financial on 8 of the 14 factors compared between the two stocks.

How does BR Biopharma compare to Cayson Acquisition?

BR Biopharma (NASDAQ:BRBI) and Cayson Acquisition (NASDAQ:CAPN) are both small-cap finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, Cayson Acquisition had 1 more articles in the media than BR Biopharma. MarketBeat recorded 2 mentions for Cayson Acquisition and 1 mentions for BR Biopharma. Cayson Acquisition's average media sentiment score of 0.69 beat BR Biopharma's score of 0.00 indicating that Cayson Acquisition is being referred to more favorably in the news media.

Company Overall Sentiment
BR Biopharma Neutral
Cayson Acquisition Positive

Company Net Margins Return on Equity Return on Assets
BR BiopharmaN/A N/A N/A
Cayson Acquisition N/A N/A N/A

BR Biopharma has higher revenue and earnings than Cayson Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BR Biopharma$2.23B0.04$31.36M$0.1452.86
Cayson AcquisitionN/AN/AN/AN/AN/A

BR Biopharma has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market. Comparatively, Cayson Acquisition has a beta of -0.07, suggesting that its share price is 107% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BR Biopharma
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Cayson Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

BR Biopharma beats Cayson Acquisition on 3 of the 5 factors compared between the two stocks.

Get BR Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for BRBI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRBI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BRBI vs. The Competition

MetricBR BiopharmaCapital Markets IndustryFinance SectorNASDAQ Exchange
Market Cap$87.39M$4.27B$12.12B$10.86B
Dividend Yield4.27%5.67%5.05%4.58%
P/E Ratio52.8623.3219.4428.63
Price / Sales0.048.405.345.15
Price / Cash2.6229.1519.7220.77
Price / Book0.541.671.713.51
Net Income$31.36M$419.50M$1.32B$394.12M
7 Day Performance-7.11%-4.23%-4.23%-8.97%
1 Month Performance-48.75%-4.26%-4.45%-11.61%
1 Year PerformanceN/A-4.18%2.12%-11.21%

BR Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BRBI
BR Biopharma
0.7721 of 5 stars
$7.40
-2.9%
N/AN/A$87.39M$2.23B52.86189
LKSP
Lake Superior Acquisition
N/A$10.31
-0.1%
N/AN/A$201.51MN/AN/A2
RILY
B. Riley Financial
0.4132 of 5 stars
$3.89
+6.3%
N/A-35.0%$147.13M$967.60M1.041,380
WTF
Waton Financial
0.3916 of 5 stars
$2.11
+5.5%
N/A-42.5%$96.47M$11.08MN/A51
SIEB
Siebert Financial
0.3923 of 5 stars
$1.88
+3.9%
N/A-45.5%$76.43M$94.20MN/A166

Related Companies and Tools


This page (NASDAQ:BRBI) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners